Shots:
- HUTCHMED has completed enrolment in its P-III (SANOVO) trial to assess Orpathys + Tagrisso as a 1L treatment of pts with locally advanced or metastatic NSCLC harboring EGFR mutation & MET overexpression; last patient was enrolled in Aug 18, 2025
- Trial will evaluate Orpathys + Tagrisso vs Tagrisso in NSCLC pts, assessing PFS as 1EP, with other endpoints incl. OS, ORR, DoR, DCR, TTR, & safety
- Additionally, topline data from P-III (SANOVO) trial is expected in H2’26, with planned congress submission for presentation, plus if favorable, the results would enable the NMPA’s sNDA submission
Ref: HUTCHMED | Image: HUTCHMED | Press Release
Related News:- HUTCHMED Reports Enrollment Completion in P-II Trial of Savolitinib for Gastric Cancer in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
